Index

Note: numbers in bold type refer to figures; figures on CD-ROM are cited in index as CD-ROMFig.1 etc.

acenocoumon use in PE, 544–546
acetazolamide use in OSAHS, 458
Achromobacter xylosoxidans in cystic fibrosis, 400
active cycle of breathing technique in bronchiectasis, 354
acupuncture use in asthma, 198
acute cough, see under cough
acute interstitial pneumonia, 478
acute respiratory failure,
after extubation, 435
bronchiectasis and, 435
causes of, 429
chest trauma and, 434
CPAP cf. usual care alone, 431–433
cystic fibrosis and, 435
definitions of, 429
in asthma, 434
in COPD, 430
in pneumonia, 433
in the immunosuppressed, 434
management of, 430
non-invasive ventilation in, 429–436
predictors of success, 436
adalimumab use in sarcoidosis, 500, 502
adenocarcinoma diagnosis from pleural effusion, 526
adenosine triphosphate use in cystic fibrosis, 367, 368
adherence,
in asthmatics, 91–102
age and differences in, 97
cultural and national differences in, 97
delivery route and, 98
education and income differences in, 97
incorrect reasoning and, 100
levels of, 92, 96
measurement of, 92
non-intentional non-adherence, 100
outcome and, 99
psychological factors, 98
self-management and, 100
approach to improving, 101
studies using objective measures, 93, 94
studies using peak-flow monitoring, 96
studies using self-report, 95
in COPD trials of combination therapy cf. single agent therapy, 273
to tuberculosis treatment, 325–328
encouragement of, 327
strategies to promote, 329–331
withdrawals from COPD clinical trials, 269
adrenal function and inhaled corticosteroid side-effects, 157
adverse events, see under side-effects
advice effectiveness in smoking cessation interventions, 119
aerobic fitness measurement, 25
agammaglobulinaemia and bronchiectasis, 350
age,
differences in adherence to asthmatic medication and, 97
FEV changes with, 28
FVC changes with, 28
air travel and use of oxygen therapy in COPD, 470
airtrapping at expiratory CT, 59, CD-ROMFig.44
airway clearance techniques,
chest physiotherapy, 369
comparison of techniques, 368, 369
Flutter device, 369
in bronchiectasis, 353
in cystic fibrosis, 368
types of, 353
airway function in asthma and efficacy of inhaled corticosteroids, 148
airway hyper-responsiveness, 262
Achaligenes xylosoxidans in cystic fibrosis, 366
allergen avoidance in asthma, 194, 196
allergen immunotherapy in asthma, 193, 195
allergic bronchopulmonary aspergillosis, 351
description, 211
in cystic fibrosis, 363
treatment,
antifungal agents, 212
corticosteroids, 211
allergic rhinitis, 15
alteplase, 546
alveolar damage in acute interstitial pneumonia, 478
alveolar dead-space measurements in pulmonary embolism, 72
alveolar diffusing capacity measures of integrity, 30
alveolar volume (VA), measurements of, 30
alveolitis, cryptogenic fibrosing, 477–486
amantadine, 340
cf. placebo, 343
cf. rimantadine, 343
amiloride,
use in cystic fibrosis, 368
use in cystic fibrosis exacerbations, 381
aminophylline,
intravenous, use in acute exacerbations of COPD, 236
use in OSAHS, 458
amoxicillin use in acute exacerbations of COPD, 392
amphotericin B, use in allergic bronchopulmonary aspergillosis, 212
amyotrophic lateral sclerosis, spirometry measures in, 28
anabolic hormones, supplements in respiratory rehabilitation, 423
angiotensin-converting enzyme inhibitors and cough, 13
anistreplase, 546
Anthonisen classification, 239
Anthonisen criteria, 239
anti-immunoglobulin E use in asthma, 224
anti-inflammatory agents in bronchiectasis, 355
anti-leukotrienes,
addition of vs. dose-doubling of inhaled corticosteroids for improved asthma control, 176, 177
asthma exacerbations when given as add-on to inhaled corticosteroids, 176
cf. long-acting β-2 agonists as add-on to inhaled corticosteroids in asthma, 177, 179
administration in pregnancy, 552
clinical summary, 553
use in pulmonary hypertension, 562, 563
antidepressant use in smoking cessation, 117
antifibrotic agent use in cryptogenic fibrosing alveolitis, 483
antifungal agent use in allergic bronchopulmonary aspergillosis, 212
antihistamine use in allergic rhinitis, 15
antimalarial agents,
toxicity of, 499
use in sarcoidosis, 498
antioxidant therapy in cryptogenic fibrosing alveolitis, 482
antiviral agents,
eligibility criteria for trials of, 342
for influenza virus infection, 340
ion channel blockers,
reverse effects, 340
efficacy, 340
neuraminidase inhibitors,
reverse effects, 343
efficacy, 341
outcome measures, 343
recommendations for use, 344
apnoea,
definition, 448
see also OSAHS
apnoea/hypopnoea index, 448
argatroban, 543
arterial blood gases,
in COPD vs. interstitial lung disease, 470
useless in pulmonary embolism diagnosis, 72
ascites,
diaphragm elevation by,
on CT, 42, 43
on X-ray, CD-ROM Fig. 6
Aspergillus sp. role in bronchiectasis, 351
Aspergillus fumigatus, specific antibodies for in hypersensitivity pneumonitis, 513
aspiration,
use in primary pneumothorax, 522
use in secondary pneumothorax, 523
asthma,
acupuncture and, 198
acute, role of newer agents in, 131
acute exacerbations of, 123–132
acute respiratory failure and, 434
adherence to medication use in, 91–102
and rate of recovery, 238
Anthonisen criteria for use, 239
choice of patients that will benefit, 239
use in acute exacerbations of cystic fibrosis, 379–382, 401
choice of, 401
combination intravenous therapy, 401
combinations of, 402
single intravenous therapy, 401
use in bronchiectasis, 389–411
use in bronchitis, 303
use in COPD, 389–411
use in cystic fibrosis, 389–411
use in sinusitis, 303
when to give in acute exacerbations of cystic fibrosis, 404
when to give in COPD exacerbations, 396
antibodies,
monoclonal anti-interleukin-5 antibody treatment of asthma, 227
specific found in hypersensitivity pneumonitis, 513
anticholinergic agents,
addition to β-agonists and hospitalization of asthmatics, 126
cf. β-agonists for acute exacerbations of COPD, 234
pharmacology of, 245
side-effects of cf. those of other bronchodilators in COPD, 254
use in COPD, 245–254
anticoagulants,
oral, 544

Index
bronchoprovocation and prediction of, 22
BTS guidelines for β-2 agonists use in, 137

case scenarios
of acute exacerbation, 123
for β-agonist use, 137
childhood, long-acting β-2 agonists for, 143
chronic, long-acting β-2 agonists
vs. short-acting β-agonists in stable, 142
vs. theophylline in, 143
for stable, 140, 142
chronic therapy with β-agonists, 135–144
clinical questions, 123
combined inhalers for,
cf. individual administration of drugs, 218, 219
strategies for use, 221
comparison of combination therapies with individual drugs, 218
complementary medicine for, 193–203
COPD coexistence with, 205
costs of adjustable dosing with Symbicort® in, 223
dietary interventions and, 196
cost of adjustable dosing with Symbicort® in, 223
dietary interventions and, 196
fish oil supplements, 197
magnesium supplements, 197
salt reduction, 197
selenium supplements, 197
vitamin C supplements, 197
differentiation from COPD by bronchodilator response, 28
difficult, 205–215
case scenario, 205
differential diagnosis of, 206
dose response
of beclomethasone dipropionate, 150
of budesonide, 152
of fluticasone propionate, 152
drug dosing in acute, 128
education cf. usual care, 185
education programmes, 183–190
emergency department education, 189
exacerbations, with anti-leukotrienes cf. β-2 agonists as add-on to inhaled corticosteroids, 180
exacerbations whilst on anti-leukotrienes cf. placebo as add-on to inhaled corticosteroids, 176
flow–volume loop for, 26
fluticasone propionate cf. placebo, 153
future management with combination inhalers, 223
gains in control, 158
inhalers cf. nebulizers and, 125
inhaled corticosteroids
of beclomethasone dipropionate, 150
of budesonide, 152
of fluticasone propionate, 152
inhaled corticosteroid use and, 130
patient education and, 131
systemic corticosteroid use and, 129, 130
relaxation and, 199, 201
self-management, 185
components, 186
effect on hospitalization rate, 186
optimal pharmacotherapy and, 186
outcomes after, 186
self-management in, 100
treatment-resistant,
allergic bronchopulmonary aspergillosis and, 211–213
causes of loss of control, 206
Churg–Strauss syndrome, 214
cyclosporin for, 207, 209
dapson for, 211
description of, 205
gold for, 207, 209
hydroxychloroquine for, 210
immunoglobulin for, 210
management of, 214
methotrexate for, 206
nebulized lignocaine for, 211
search for treatments, 206
second-line immunosuppressive therapy, 207
troleandomycin for, 209
useful tests in diagnosis, 30
wheeze as predictor of, 21
written action plans, 187
effect on hospitalization rate, 188
outcome and, 187, 188
yoga and, 199, 202
atelectasis,
appearance on X-ray, 46, 47
autopsy, identification of pulmonary embolism at, 66
azathioprine,
toxicity of, 499
use in cryptogenic fibrosing alveolitis, 480, 481
use in sarcoidosis, 499, 501
azlocillin,
use with penicillin in cystic fibrosis, 402
use with tobramycin in cystic fibrosis, 402
azoles, use in allergic bronchopulmonary aspergillosis, 212
bacillus Calmette–Guérin in tuberculosis prevention, 325
bacteria,
as a cause of hypersensitivity pneumonitis, 510
role in acute exacerbations of COPD, 397
see also by species name
sputum cultures
for bronchiectasis, 352
in cystic fibrosis, 366
Beck Depression Inventory, 452
beclomethasone dipropionate,
airway function and, 148
cf. fluticasone, 154
cf. placebo, 151
in treatment of, 147–159
late-onset, 15
monoclonal anti-interleukin-5 antibody treatment of, 227
monotherapies for, 169
national guidelines for diagnosis and management, 30
non-pharmacological interventions, 193–203
novel therapies, 217–228
outcomes and education, 184, 185
pharmacoeconomic studies of combined inhalers for, 223
prediction from methacholine challenge, 21
predictive symptoms for, 21
primary-care based settings for education, 188
provision of information on, 183
relapse,
inhaled corticosteroid use and, 130
patient education and, 131
systemic corticosteroid use and, 129, 130
relaxation and, 199, 201
self-management, 185
components, 186
effect on hospitalization rate, 186
optimal pharmacotherapy and, 186
outcomes after, 186
self-management in, 100
treatment-resistant,
allergic bronchopulmonary aspergillosis and, 211–213
causes of loss of control, 206
Churg–Strauss syndrome, 214
cyclosporin for, 207, 209
dapson for, 211
description of, 205
gold for, 207, 209
hydroxychloroquine for, 210
immunoglobulin for, 210
management of, 214
methotrexate for, 206
nebulized lignocaine for, 211
search for treatments, 206
second-line immunosuppressive therapy, 207
troleandomycin for, 209
useful tests in diagnosis, 30
wheeze as predictor of, 21
written action plans, 187
effect on hospitalization rate, 188
outcome and, 187, 188
yoga and, 199, 202
atelectasis,
appearance on X-ray, 46, 47
autopsy, identification of pulmonary embolism at, 66
azathioprine,
toxicity of, 499
use in cryptogenic fibrosing alveolitis, 480, 481
use in sarcoidosis, 499, 501
azlocillin,
use with penicillin in cystic fibrosis, 402
use with tobramycin in cystic fibrosis, 402
azoles, use in allergic bronchopulmonary aspergillosis, 212
bacillus Calmette–Guérin in tuberculosis prevention, 325
bacteria,
Index

cf. inhaled corticosteroids, 139
 cf. inhaled corticosteroids in asthma, 143
 chronic therapy with, 135–144
 Cochrane reviews of regular use, 138
 combined with ipratropium bromide, for acute exacerbations of COPD, 236
 current guidelines for use, 136
daytime symptoms with, 141
 FEV after treatment of COPD cf. anticholinergic agents, 235
 long-acting,
 combined with inhaled corticosteroids, see also LABAICS
 combined with inhaled corticosteroids in COPD, 267–275
 combined with inhaled corticosteroids, 218
 cf. leukotriene antagonists, 220
 pharmacoeconomic studies, 223
 safety of cf. other regimens, 221
 Seretide® cf. individual drug administration, 217
 Seretide® cf. inhaled steroids alone, 219
 strategies for use, 221
 use in asthma, 217
 long-acting in childhood asthma, 143
 long-acting vs. placebo, 138
 long-acting vs. short-acting β-agonists, 138
 in stable asthma, 142
 long-acting vs. theophylline, 138
 in chronic stable asthma, 143
 long-acting with inhaled corticosteroids, 144
 long-term use in stable chronic asthma, 140, 142
 safety and efficacy, 144
 short-acting for acute exacerbations of COPD, 234
 short-acting vs. placebo, 138
 side-effects cf. theophylline, 143
 with inhaled corticosteroids cf. inhaled corticosteroids alone, 144
 β-agonists,
 addition of anticholinergic agents to and hospitalization of acute asthmatics, 126
 cf. ipratropium bromide for prevention of COPD exacerbations, 251
 cf. over-the-counter cough medicines, 306
 chronic therapy with, 135–144
 definitions of, 135
 history of use, 135
 inhaled, cf. ipratropium bromide for COPD exacerbations, 234
 long-acting,
 additive effect in COPD with inhaled corticosteroids, 270
 cf. ipratropium bromide in COPD, 249
 role in acute asthma, 131
 use in cystic fibrosis, 377
 short-acting,
 alone cf. with inhaled corticosteroids in COPD, 262
 bronchodilating effect of, 246
 cf. ipratropium bromide in COPD, 246
 combined with ipratropium bromide cf. alone in COPD, 249
 use in cystic fibrosis, 376
 short-acting vs. long-acting β-2 agonists in stable asthma, 142
 use for acute cough and bronchitis, 305
 vs. β-2 agonists, 138
 β-lactams,
 cf. macrolides, in COPD, 392
 cf. quinolones, in COPD, 392, 394, 395
 use in acute exacerbations of COPD, 392
 bilevel ventilatory support in cystic fibrosis, 378
 biochemical markers for osteoporosis, 107
 biopsy, needle biopsy of pleura, 527
 bisphosphonates, use in osteoporosis, 111
 bivalirudin, 543
 blood gases, arterial,
 in COPD vs. interstitial lung disease, 470
 useless in pulmonary embolism diagnosis, 72
 bolus thrombolysis, 549
 bone densitometry, measures of in cystic fibrosis management, 367
 bone density changes on budesonide therapy, 263
 bone metabolism,
 effect of oral corticosteroids on in COPD, 282
 inhaled corticosteroids and, 110, 263
 oral corticosteroids and, 108
 bone mineral density, in COPD patients on corticosteroids, 109, 110
 Bordetella pertussis in bronchitis, 301
 bosentan use in arterial pulmonary hypertension, 563
 Branhamella catarrhalis in bronchiectasis, 352
 breathing techniques in asthma, 199
 bronchial hyper-reactivity and wheezing, 21
 bronchiectasis, 349–357
 acute exacerbations of, 356
 choice of antibiotics for, 398
 efficacy of antibiotics for, 398
 indications for antibiotics in, 399
 use of antibiotics for, 398
 aetiology, 349
 antibiotic studies in, 399, 400
 appearance on X-ray, 351, CD-ROMFig.25
 bacteria responsible for, 352
 clinical implications of antibiotic studies in, 407
 clinical practice points, 357
 clinician’s summary of antibiotic use in, 408
 cylindrical, 349
 cystic, 349
 epidemiology, 350
 high-resolution CT diagnosis of, 350
 in COPD, 350
 in cystic fibrosis, 362, 366
 infection in, 397
 initiating events, 349
 investigations of, Aspergillus serology, 351
 assessment of functional capacity, 352
 assessment of quality of life, 353
 immunoglobulin levels, 350
 lung function testing and, 352
 nasal and expired nitric oxide levels, 352
 radiographic, 350
 sputum bacterial culture, 352
 sweat electrolyte analysis, 351
 maintenance antibiotic therapy in, 399
 management of, 353
 acute exacerbations, 357
 airway clearance techniques, 353
 anti-inflammatory agents, 355
 bronchodilators, 356
 chronic techniques, 353
 DNase in, 354
 inhaled hyperosmolar agents, 354
 long-term antibiotics, 355
 long-term oxygen therapy, 356
 lung transplantation, 356
 mucolytics in, 354
 physical training and, 355
 resectional surgery, 356
 non-invasive ventilation in acute respiratory failure of, 435, 436
 pathophysiology, 349
 bronchiolitis, pulmonary nodules in, 57
 bronchitis, 301–307
 after viral nasopharyngitis, 301
 as a complication of influenza virus infection, 335
 bacteria causing, 301
 chronic, tramline opacities on X-ray; CD-ROMFig.25
 clinical course, 302
 comparative efficacy and cost of treatments, 307
 definition, 301
 diagnosis, 301, 302
 key points, 307
 prevalence, 301
 RCT on, 304, 305
treatments for,
  antibiotics, 303
  antibiotics cf. placebo, 304
  β-agonists, 305
  β-agonists cf. over-the-counter cough medicines, 306
  over-the-counter cough medicines, 304, 305
  patient expectations, 306, 307
  side-effects of, 306
  variations in management by GPs, 302
bronchoalveolar cell carcinoma, appearance on X-ray, CD-ROM Fig. 18
bronchoalveolar lavage,
  characteristics of fluid from hypersensitivity pneumonitis, 516
  use in hypersensitivity pneumonitis diagnosis, 515
bronchodilator response,
  national guidelines for, 29
  use in differentiating asthma from COPD, 28
bronchodilators,
  therapy in cystic fibrosis, 377
  use in cystic fibrosis exacerbations, 381
bronchopneumonia, appearance on X-ray, CD-ROM Fig. 17
bronchoprovocation use in asthma prediction, 22
bronchoscopy,
  cf. CT for haemoptysis, 17
  use in undiagnosed pleural effusion, 527
  BTS guidelines for β-2 agonists use in asthma, 137
budesonide,
  use in cystic fibrosis exacerbations, 381
Burkholderia cepacia in cystic fibrosis, 362, 363, 366, 400
burns as adverse effect of long-term oxygen therapy, 465, 466
buspirone use in OSAHS, 458
Butetko method use in asthma, 199
calcifications,
  causes of pulmonary, 52
  pulmonary nodules and, 48, CD-ROM Fig. 20
calcitonin in osteoporosis, 112
calcium in osteoporosis with vitamin D, 112
  calcium channel blockers in arterial pulmonary hypertension, 567
  carcinoembryonic antigen in diagnosis of pleural effusion, 526
carcinoma of trachea, flow–volume loop for, 26
cardiac arrhythmia after cisapride therapy, 16
cardiac biomarkers useless in pulmonary embolism diagnosis, 72
cardiac failure appearance on X-ray, CD-ROM Fig. 24
cardiomyopathy as a cause of dyspnoea, 20
cardiopulmonary disease, pulmonary embolism presentation in patients without previous, 64
catheter transvenous embolectomy, 551
ceftazidime, nebivolized vs. placebo, 405
cepacia syndrome, 363
cephalosporins,
  cf. cotrimoxazole in COPD, 392
  cf. penicillins in COPD, 392
  use in acute exacerbations of COPD, 392
chest physiotherapy for cystic fibrosis exacerbations, 381
chest wall,
  abnormal decrease in density, 39
  following mastectomy, 39, CD-ROM Fig. 2
  abnormal increase in density, 39, 40, CD-ROM Fig. 1
  CT vs. X-ray and MRI, 39
  examination techniques and findings, 39
Chlamydia pneumoniae in bronchitis, 301
chlorambucil use in sarcoidosis, 499, 501
chloroquine use in sarcoidosis, 498
chronic cough, see under cough
chronic heart failure cf. chronic lung disease, 18
chronic lung disease cf. chronic heart failure, 18
chronic obstructive pulmonary disease (COPD),
  acute exacerbations of, 233–242, 261, 268
  Anthonisen criteria, 239
  antibiotics and rate of recovery, 238
  as a cause of acute respiratory failure, 429
  balancing benefits with side-effects of systemic corticosteroids, 240
  β-agonist cf. ipratropium bromide as treatment, 234
  choice of antibiotics for, 392
  choice of patients to receive antibiotics, 239
  combination therapies for, 236
  double-blind antibiotic comparisons in, 393
  drug doses for, 235
  FEV after treatment with anticholinergic agents cf. β-agonists, 235
  guidelines for clinicians, 241
  guidelines for methylxanthine use in, 236, 237
  infections in, 390
  intravenous aminophylline and lung function, 236
  ipratropium bromide combined with β-agonists for, 236
  non-invasive ventilation cf. standard care, 238, 431
  non-invasive ventilation use and complications, 237
  on combination therapy cf. single agent therapy, 272, 274
  prednisone cf. placebo in, 240
  prevention of, 251
  by tiotropium, 254
  RCT on use of antibiotics in, 390, 391
  recommended management, 234
  role of bacteria in, 397
  role of infections in, 238
  search results for antibiotic use in, 390
  suggested treatment approach, 241
  systemic corticosteroid and hospitalization with, 237
  use after and relapse, 239
  use of antibiotics in, 390
  when to give antibiotics for, 396
  acute respiratory failure in, 430
  additive effect of long-acting β-agonists with inhaled corticosteroids in, 270
  air travel and oxygen therapy in, 470
  airway hyper-responsiveness in, 262
  anticholinergic agent use, summary for clinicians, 254
  anticholinergic bronchodilators in, 245–254
  arterial blood gas in cf. interstitial lung disease, 470
  as a cause of dyspnoea, 20
  assessment of patients for long-term oxygen therapy, 463
  bone density changes and treatment, 263
  bone metabolism changes and oral corticosteroids, 282
  bone mineral density in, 109, 110
  breathlessness on combination therapy cf. single agent therapy, 272
  bronchiectasis in, 350
  case scenario, 267, 277, 285
  clinical implications of antibiotic studies in, 407
  clinical questions, 269
  clinical recommendations for use of inhaled corticosteroids, 264
  clinical trials of FEV and inhaled corticosteroid use, 258
  clinical trials of LABAICS in, 267
  clinician’s summary of antibiotic use in, 408
  coexistence with asthma, 205
  combination therapy cf. single agent therapy, 272
  common presentation at emergency department, 233
  cough as presenting symptom in smokers, 13
  dangers of smoking whilst using oxygen therapy for, 466
  description, 233
  of problem, 439
  of treatment, 439
dyspnoea after respiratory rehabilitation for, 422
early studies of inhaled corticosteroid use in, 257
effect of inhaled corticosteroids on inflammation, 261
effect of oxygen therapy:
on exercise capacity, 466, 469
on quality of life, 466, 469
effect of tiotropium on symptoms and health status in, 254
effect of triamcinolone on lung function in, 260
efficacy of inhaled corticosteroids in, 249, 250
efficacy of long-term oxygen therapy for, 463
efficacy on combination therapy cf. single agent therapy, 275
GOLD guidelines for, 261
GOLD recommendations in, 275
health status and breathlessness, 268
health status on combination therapy cf. single agent therapy, 273
hospitalization and inhaled corticosteroid use in, 262
hyperinflation in, 440
improvement on combination therapy cf. single agent therapy, 274
inclusion criteria for clinical trials, 268
influenza vaccination and relapse, 240, 241
inhaled corticosteroids combined with long-acting β-2 agonists in:
267–275
inhaled corticosteroids for, 257–264
ipratropium bromide:
cf. long-acting β-agonists for, 249
cf. short-acting β-agonists as bronchodilator, 246
combined with short-acting β-agonists cf. agents alone, 249
literature search on rehabilitation, 418
long-term nocturnal non-invasive ventilation for, 444
long-term oxygen therapy for chronic respiratory failure in, 463–470
long-term oxygen therapy vs. no oxygen therapy, 465
long-term studies of inhaled corticosteroids and FEV in, 258
lung function improvement on oral corticosteroids cf. placebo, 278
lung volume reduction, 285–295
lung volume reduction surgery for,
adverse events, 292
anaesthetic technique, 287
beneficial effects, 289
comparative efficacy and cost, 294
comparison of techniques, 289
effect on survival, 292
effects on dyspnoea, 289
effects on exercise capacity, 290
effects on FEV, 289
effects on lung volume, 290
effects on oxygenation requirement, 290
exclusion criteria for patients, 289
inclusion criteria for patients, 288
long-term outcomes, 293
mechanisms of action, 286
mortality after, 289
patient assessment algorithm, 288
postoperative management, 289
prediction of response, 292
preoperative assessment for, 287
RCT results, 290
summary for clinicians, 295
summary of treatment effects, 291
surgical technique, 287
maintenance antibiotic therapy in, 397
maintenance programmes for respiratory rehabilitation, 424
measure of FEV in, 267
mechanisms by which lung volume reduction surgery works in, 286
mortality and inhaled corticosteroid use, 264
mortality prediction in, 28
non-invasive ventilation in, 442
non-invasive ventilation:
in acute respiratory failure in, 430
in stable patients, 439
oral corticosteroids and exercise capacity, 281
oral corticosteroids cf. placebo in stable disease, 278
oxygen therapy and assisted ventilation in, 467, 468
oxygen therapy vs. no oxygen therapy, 465
prediction of response to oral corticosteroids, 282
quality of life and inhaled corticosteroid use, 262, 263
RCT of ipratropium bromide use in, 247, 248
RCT of long-term non-invasive ventilation in, 441
RCT of short-term non-invasive ventilation in, 440, 441
RCT of tiotropium use in stable COPD, 252
respiratory rehabilitation in, 417–426
results from National Emphysema Treatment Trial of lung volume reduction surgery, 291
role of patient education in prevention of relapse, 240
role of smoking in, 115
secondary pneumothorax in, 523
side-effects of combination therapy cf. single agent therapy, 273
side-effects of inhaled corticosteroid use in, 263
side-effects of oral corticosteroid use in stable, 281
smoking cessation and relapse, 240
smoking history and, 20
spirometry in screening of, 28
studies of oxygen therapy in stable COPD, 464
subjective effect of oral corticosteroids on symptoms, 279
summary for clinicians on oral corticosteroid use in, 283
symptom improvement on oral corticosteroids, 278
systemic corticosteroids in stable disease, 277–283
time spent on non-invasive ventilation, 444
tiotropium cf. placebo and lung function, 253
uncontrolled non-invasive ventilation trials in, 442
wheeze as predictor of, 22
with pulmonary hypertension, therapy of, 563
withdrawal of inhaled corticosteroid use, 263
withdrawals from clinical trials, 269
chronic respiratory failure in COPD, long-term oxygen therapy, 463–470
chronic thromboembolic disease and pulmonary hypertension, 563
Churg–Strauss syndrome,
deinition of, 214
description, 214
non-pulmonary organ involvement in, 214
treatment, 214
corticosteroids, 214
cyclophosphamide, 214
cisapride, cardiac arrhythmias after therapy with, 16
clinical follow-up in pulmonary embolism, 66
diagnostic likelihood, estimation of pretest, for pulmonary embolism, 67, 68
dlonidine,
use in OSAHS, 458
use in smoking cessation, 118
Cochrane Library,
composition of, 5
description of, 4
Cochrane systematic reviews,
allergen avoidance in asthma, 194
allergen immunotherapy in asthma, 193, 195
β-2 agonist use in asthma, 139
DNase use in cystic fibrosis, 370, 371
for clinical trials of LABAICS in COPD, 269
into steroid-induced osteoporosis management, 112
of pneumococcal vaccines in preventing community-acquired pneumonia, 315
of pneumococcal vaccines in preventing disease and death, 316, 317
on acute exacerbations of COPD, 234
on asthma education, 184
Cochrane Tobacco Addiction Review group, 115
cognitive function,
cognitive performance tests, 450, 452
effect of OSAHS on, 447
improvement in with CPAP, 455
colchicine,
use in cryptogenic fibrosing alveolitis, 482, 483
use in treatment-resistant asthma, 211
computed tomography (CT), 37–59
composite reference standard in pulmonary embolism, 66
community-acquired pneumonia, 309–318
collagen vascular diseases, 562
contrast venography use in search for residual DVT, 71
coronary artery bypass surgery, management of pleural effusion after, 529
corticosteroid-induced osteoporosis, 107–113
corticosteroids, inhaled,
additive effect with long-acting β-2 agonists in COPD, 270
airway function and, 148

airway hyper-responsiveness in COPD, 262
alone cf. with β-2 agonists, 144
anti-leukotrienes cf. placebo as add on to, 173, 174
asthma exacerbations on, 148
cf. anti-leukotrienes and exacerbations, 171
cf. β-2 agonists, 139
cf. oral in COPD, 258
cf. placebo, 151
cf. placebo in COPD, 257
characteristics of reviews on, 149
clinical measures of efficacy in asthma, 157
clinical recommendations for use in COPD, 264
clinical trials of FEV in COPD, 258
combined with long-acting β-2 agonists, see also LABAICS
combined with long-acting β-2 agonists for COPD, 267–275
comparison of anti-leukotrienes vs. placebo as add-on to, 175
comparison of doses, 150
dose response and outcome, 147
dose response in COPD, 258
eyearly studies of use in COPD, 257
effect modifiers, 157
effect on baseline lung function, 260
effect on biochemical markers, 110
effect on bone, 110
effect on bone metabolism, 263
effect on inflammation in COPD, 261
effect on lung function in COPD, 260
effect on PEF, 150
efficacy and safety of various forms, 148
history of use, 147
hypothalomo–pituitary axis side-effects, 154, 155
improvement in outcome measures and, 147
in combination with long-acting β-2 agonists, 217
cf. leukotriene antagonists, 220
cf. steroid alone, 219
cf. lifestyle strategies in OSAHS, 454
comparison of Seretide® with individual drugs, 218
pharmacoeconomic studies, 223
safety cf. other regimens, 221
Seretide®, 219
strategies for use, 221
Symbicort®, 219
increased dose cf. β-2 agonists in asthma, 143
long-acting β-2 agonists and, 144
long-term β-2 agonist use with, 141
long-term studies of FEV in COPD, 258
lowest tolerated dose, 174
mortality and use in COPD, 264
oral side-effects, 154, 155
oropharyngeal side-effects, 155
quality of life in COPD, 262
relative efficacies, 153
scale of use, 109
side-effects of cf. placebo, 154
sparing effect cf. oral steroids, 152
systemic bioavailability, 110
use and omalizumab therapy, 226
use for inflammation control in cystic fibrosis, 375
use in asthma treatment, 147–159
use in COPD, 257–264
use in mild asthma, 137
use in pulmonary sarcoidosis, 492
clinical studies of, 495, 496
use of and relapse after acute asthma attacks, 130
vs. anti-leukotrienes as monotherapy, 169, 170
withdrawal of use in COPD, 263
intravenous use of and hospitalization of acute asthmatics, 126, 127
oral, effect in patients with respiratory disease, 109
effect on biochemical markers, 109
effects on bone, 108
mechanisms of action on bone, 108
scale of use, 108
sparing effect of, 150
sparing effect of inhaled beclomethasone dipropionate on, 154
sparing effect of inhaled budesonide on, 154
sparing effect of inhaled fluticasone on, 154
use for inflammation control in cystic fibrosis, 374
use in cystic fibrosis exacerbations, 381
use in pulmonary sarcoidosis, 491
clinical studies of, 493, 494
pharmacokinetics of inhaled cf. oral, 497
sparing effect of anti-leukotrienes, 172
spirometry results and early treatment with, 30
systemic,
balance of benefit with side-effects, 240
cf. placebo in stable COPD, 278
effect on disease progression in COPD, 280
effect on FEV in COPD, 280
effect on disease progression in COPD, 280
effect on exercise capacity in COPD patients, 281
for acute exacerbations of COPD, hospitalization and, 237
in acute exacerbations of bronchiectasis, 357
lung function improvement in COPD and, 278
prediction of response in COPD, 282
prednisone cf. placebo in COPD, 240
side-effects in stable COPD, 281
subjective effect on COPD symptoms, 239
use after acute exacerbations of COPD and relapse, 239
use in active hypersensitivity pneumonitis, 517
use in chronic pulmonary sarcoidosis, 497
use in stable COPD, 277–283
use of and relapse after acute asthma attacks, 129, 130
use as adjunctive treatment in tuberculosis, 324
use in allergic bronchopulmonary aspergillosis, 211
use in Churg–Strauss syndrome, 214
use in cryptogenic fibrosing alveolitis, 479
use in sarcoidosis, 491
costs,
adjustable dosing with Symbicort® in asthma, 223
comparative efficacy of treatments for bronchitis and sinusitis, 307
cost-effectiveness
of influenza vaccine, 338
of oxygen therapy in COPD, 466
of screening for lung cancer, 86
of strategies in management of influenza, 343
of lung volume reduction surgery for COPD and comparative efficacy, 294
of pulmonary hypertension treatment, 367
pharmacoeconomic studies of combined inhaler use in asthma, 223
cotrimoxazole,
cf. cephalosporins in COPD, 392
use in acute exacerbations of COPD, 392
cough,
acute,
causes of, 13
diagnosis of cause, 13
case scenario, 15
chronic,
anatomic diagnosis of, 14
common causes, 13
diagnosis of cause, 13
rarer causes, 13
diagnostic protocol, 14
diagnostic strategies for, 13
directed coughing in bronchiectasis, 354
duration in bronchitis, 302
in cryptogenic fibrosing alveolitis, 484
in smokers, 13
psychogenic, 13
treatment of acute with over-the-counter cough medicines, 304–306
cough reflex, anatomy of afferent limb of, 14
counselling, effectiveness in smoking cessation interventions, 119
CPAP, see under continuous positive airway pressure
Crohn’s disease, 350
cryptogenic fibrosing alveolitis, 477–486
clinical course, 477
diagnosis, 477
disease-modifying therapy, 479
antifibrotic agents, 483
antioxidant therapy, 482
azathioprine, 480, 481
colchicine, 482, 483
cyclophosphamide, 480, 481
cyclosporine A, 480, 481
glutathione, 482
immunosuppressive agents used in, 480
interferon-gamma, 482, 483
methotrexate, 480, 482
new agents used in, 482
penicillamine, 480, 482
pirfenidone, 482, 483
use of corticosteroids, 479
palliation, 486
pulmonary hypertension in, 485
search strategy used for, 478
summary for clinicians, 486
symptom control, cough, 484
hypoxaemia, 484
pulmonary hypertension, 485
reflux oesophagitis, 484
CT, see under computed tomography
culture, differences in adherence to asthmatic medication and, 97
cyclophosphamide,
toxicity of, 500
use in Churg–Strauss syndrome, 214
use in cryptogenic fibrosing alveolitis, 480, 481
use in sarcoidosis, 499, 501
cyclosporin,
use in cryptogenic fibrosing alveolitis, 481, 480
use in sarcoidosis, 502, 503
use in treatment-resistant asthma, 207, 209
cystic fibrosis, 361–382
acute exacerbations of, 381
antibiotic use in, 400
choice of antibiotics for, 401
combination of intravenous antibiotics for, 401, 402
do antibiotics work in, 401
management of, 379
single intravenous antibiotics for, 401
when to give antibiotics, 404
antistaphylococcal antibiotic therapy in, 405, 406
as a cause of acute respiratory failure, 429
bilevel ventilatory support in, 378
bronchiectasis in, 366
bronchodilatory therapy, 377
chronic management, 367
clinical implications of antibiotic studies in, 407
clinician’s summary of antibiotic use in, 408
diagnosis, 364
diffuse panbronchiolitis in, 376
DNase use, 370, 371
epidemiology, 361
exacerbations of,
amiloride for, 381
antibiotics for, 379–381
bronchodilators for, 381
chest physiotherapy for, 381
DNase for, 381
hospitalization for intravenous antibiotics in, 380
hyperosmolar agents for, 381
intensive care unit admission for, 382
non-invasive ventilation for, 382
exercise, 448
excessive daytime sleepiness, 448
evidence-based medicine (EBM), 448
evidence, 448
Euroscop study, 259, 261
etanercept use in sarcoidosis, 500, 502
Epworth Sleepiness Scale, 449, 451
eoprostopenol use in arterial pulmonary hypertension, 564
etanercept use in sarcoidosis, 500, 502
Euroscop study, 259, 261
evidence, 448
from Cochrane collaboration, 4
from RCT, 4
from systematic reviews, 4
interpretation of, 9
Level I, 4,
Level II, 4,
Level III, 4,
Level IV, 4,
Level V, 4
levels available on lung volume reduction surgery in COPD, 286
levels of, 3
location of, 7
search strategies for, 8
evidence-based medicine (EBM), 448
description, 3–9
example of, 3
in respiratory care, 8
reasons for use, 3
websites used in, 9
excessive daytime sleepiness, 448
exercise, 448
capacity for in COPD and oral corticosteroids, 281
effect of lung volume reduction surgery on capacity, 290
effect of oxygen therapy on capacity, 466, 469
effect on OSAHS, 458
efficacy of ipratropium bromide cf. other agents in COPD for maintaining, 251
functional capacity for and rehabilitation, 419
inspiratory muscle training, 419
maintenance of, 425
maximal capacity and rehabilitation, 419
oxygen supplementation during exercise training, 423
physical training in bronchiectasis, 355
physical training in cystic fibrosis management, 369
training for respiratory rehabilitation, 417
use of oxygen therapy in COPD and, 466
ventilatory support during training, 424
exercise challenge in asthma cf. COPD, 30
exercise testing, 25
surgical risk prediction from, 31
extubation, acute respiratory failure after, 435, 436
farmer’s lung, 510
high-resolution CT of, 512
lung function and corticosteroid use, 517
prevention measures, 517
fat-soluble vitamins, measures of in cystic fibrosis management, 367
FEV, see under functional expiratory flow
fibreoptic bronchoscopy in diagnosis of haemoptysis, 17
fibrinolytics,
see also thrombolytic agents
use in parapneumonic effusion therapy, 530
fibrosing alveolitis associated with systemic sclerosis, 479
fish oil supplementation and asthma, 197
fixed major airway obstruction, flow–volume loop for, 26
floppy extrathoracic airway obstruction, flow–volume loop for, 26
flow–volume loop, examples of, 26
fluoride, use in osteoporosis, 112
fluticasone,
airway function and, 148
cf. beclomethasone dipropionate, 154
cf. budesonide, 154
cf. placebo, 153
cf. placebo in COPD, 258
cf. sameterol, 144
cf. placebo in COPD, 258
cf. placebo, 155
cf. anti-leukotrienes as monotherapy, 170
vs. beclomethasone dipropionate and budesonide for efficacy, 156
vs. beclomethasone dipropionate and budesonide for safety, 155
flutter in bronchiectasis, 354
Flutter device, 369
forced expiratory technique in bronchiectasis, 354
formoterol,
cf. ipratropium bromide in COPD, 249, 250
combined with budesonide in turbuhaler, 144
fracture,
airway function and, 148
cf. beclomethasone dipropionate, 154
combined with budesonide in turbuhaler, 144
risk and corticosteroid dose, 108
risk of, 107, 108
see also osteoporosis
France, lung cancer screening trials in, 85
fumaric acid esters in sarcoidosis, 503, 504
functional expiratory flow (FEV), 448
additive effect of long-acting -agonists with inhaled corticosteroids on in COPD, 271
as a measure of COPD outcome, 267
as a measure of hospitalization in asthmatics, 124
as a predictor in COPD, 28
changes through time in cystic fibrosis, 362
changes with age, 28
clinical trials of inhaled corticosteroids in COPD, 258
difference between treatments of COPD and, 271
effect of lung volume reduction surgery on, 290
improvement in COPD patients on oral corticosteroids cf. placebo, 278, 280
in cystic fibrosis with antibiotic therapy, 403
in hypersensitivity pneumonitis, 513
levels in responders to inhaled corticosteroids in COPD, 258
measures before lung resection, 31
national guidelines for, 29
on ipratropium bromide cf. -agonists in COPD, 235
preoperative risk assessment and, 31
hypertension, pulmonary, see under pulmonary hypertension
hypertonic saline, use in cystic fibrosis management, 371, 372
hypogammaglobulinaemia and bronchiectasis, 350
hypnoxaemia in cryptogenic fibrosing alveolitis, 484
idiopathic interstitial fibrosis, appearance on CT, CD-ROMFig.37
idiopathic interstitial pneumonia, 477
iloprost,
infliximab in sarcoidosis, 500, 502
inflammation, infection, indwelling catheter, use in malignant pleural effusions, 528
income, differences in adherence to asthmatic medication and, 97
immunotherapy in asthma, 193
immunoglobulin, immunization, influenza vaccine and COPD relapse, 240, 241
interferon-gamma use in cryptogenic fibrosing alveolitis, 482, 483
interstitial lung disease, arterial blood gas in cf. COPD, 470
as a cause of dyspnoea, 20
diffusing capacity measures in, 30
interstitial lung disease in rheumatoid arthritis, 479
interstitial pneumonitis, 509–518
inhalation challenge for hypersensitivity pneumonitis, 515
inhalation therapy, role in clinical questions, 6
inhaled hyperosmolar agents in bronchiectasis, 354
inhaled, cf. inhaled
Symbicort®, 219, 221
Seretide®, 219, 221
Nebulized, 248
Nebulized therapy, 241
combination forms, 249
combination with corticosteroids and long-acting beta-agonists, 249
combined with short-acting beta-agonist in COPD, 246
combined with long-acting beta-agonists in COPD, 246
combined with short-acting beta-agonist in COPD cf. alone, 249
doses for acute exacerbations of COPD, 235
efficacy in COPD cf. other agents, 249, 250
inhaled, cf. inhaled beta-agonist for acute exacerbations of COPD, 234
new propellant with, 249
pharmacological properties of, 245, 246
RCT in COPD, 247, 248
see also anticholinergic agents

neuraminidase inhibitors,
adverse effects, 343
efficacy, 341
outcome measures, 343
recommendations for use, 344
background description, 335
biology of, 335
complications of, 335
control measures,
cost-effectiveness of vaccination, 338
inactivated vaccines, adverse effects, 338
efficacy, 336, 337
policies for and implementation of, 339
target groups for vaccination, 339
vaccination administration to people at risk of community-acquired pneumonia, 314
cost-effectiveness of strategies in management of, 343
incidence of infection, 335
laboratory diagnosis of infection, 335
prognosis, 335
summary for clinicians, 344
vaccination and treatment, 335–344
information, access to, 3
provision of, on asthma, 183
see also evidence
inhalation challenge for hypersensitivity pneumonitis, 515
inhaled hyperosmolar agents in bronchiectasis, 354
inhaled, cf. nebulization and hospitalization of asthmatics, 125
combination forms, 249
adjustable dosing, 222
future use of in asthma management, 223
Symbicort®, 219, 221
electronic monitoring of, 92
new propellant with ipratropium bromide, 249
interferon-gamma use in cryptogenic fibrosing alveolitis, 482, 483
interstitial lung disease, arterial blood gas in cf. COPD, 470
as a cause of dyspnoea, 20
diffusing capacity measures in, 30
interstitial lung disease in rheumatoid arthritis, 479
interstitial pneumonitis, 477
interventions, role in clinical questions, 6
intrapleural fibrinolytics, 530
intubation in acute respiratory failure after non-invasive ventilation cf. usual medical care, 432
iodopovidone, use in pleurudosis, 528
ion channel blockers, adverse effects, 340
efficacy, 340
meta-analysis for, 342
ipratropium bromide,
bronchodilating effect of, 246
cf. formoterol in COPD, 249, 250
cf. long-acting beta-agonist in COPD, 249
cf. other agents for prevention of COPD exacerbations, 251, 253
cf. salmeterol in COPD, 250
cf. short-acting beta-agonists in COPD, 246
combined with beta-2 agonists for acute exacerbations of COPD, 236
combined with short-acting beta-agonist in COPD cf. alone, 249
doses for acute exacerbations of COPD, 235
efficacy in COPD cf. other agents, 249, 250
inhaled, cf. inhaled beta-agonist for acute exacerbations of COPD, 234
new propellant with, 249
pharmacological properties of, 245, 246
RCT in COPD, 247, 248
see also anticholinergic agents
lung cancer, 541–543

long-term oxygen therapy, 31

lobeline in smoking cessation, 118

liver function tests in cystic fibrosis management, 367

lipomatosis, mediastinal, 43, CD-ROMFig.9

lignocaine use of nebulized in treatment-resistant asthma, 211

Light's criteria, 524

leflunomide use in sarcoidosis, 499, 501

Legionella in community-acquired pneumonia, 311

lepirudin, 543

leukotriene agonist use in cystic fibrosis, 377

leukotriene antagonists, comparison with inhaled corticosteroids in combination with long-acting β-2 agonists, 220

lifestyle strategies cf. CPAP in OSAHS treatment, 454

Kleebsella sp., bronchiectasis and, 349

LABAICS (long-acting β-agonists with inhaled corticosteroids), additive effect on lung function in COPD, 270, 271

breathlessness, 272

cf. therapy with individual agents, 270–274

clinical trials of in COPD, 267

drop-out rates on, 273, 274

exacerbation rates in COPD and, 272

see also β-agonists; corticosteroids

lactate dehydrogenase, separation of transudates from exudates by, 524

lanotepalase, 546

laser therapy as adjunctive treatment in tuberculosis, 325

laser-assisted uvulopalatoplasty, adverse effects after, 459

efficacy in OSAHS, 459

late-onset asthma, see under asthma

leflunomide use in sarcoidosis, 499, 501

Legionella in community-acquired pneumonia, 311

lepirudin, 543

leukotriene agonist use in cystic fibrosis, 377

leukotriene antagonists, comparison with inhaled corticosteroids in combination with long-acting β-2 agonists, 220

role in acute asthma, 131

lifestyle strategies cf. CPAP in OSAHS treatment, 454

Light's criteria, 524

lignocaine use of nebulized in treatment-resistant asthma, 211

lipomatosis, mediastinal, 43, CD-ROMFig.9

liver function tests in cystic fibrosis management, 367

lobeline in smoking cessation, 118

long-term oxygen therapy, administration, 463

adverse effects, 465

assessment of patients for, 463

continuous vs. nocturnal, 463

efficacy, 463

for chronic respiratory failure in COPD, 463–470

implications for practice, 465

in stable COPD, 464

rationale for use, 463

use in cystic fibrosis, 378

vs. no oxygen therapy, 465

low-molecular-weight heparin, 541–543

lung biopsy, surgical, 516

transbronchial, 516

use in hypersensitivity pneumonitis diagnosis, 515

lung cancer, early intervention, 81

incidence, 81

low-dose spiral CT for screening, 83

morbidity and screening, 82

mortality and screening, 82

natural history of disease, 81

screening for, 81–86

smoking and, 81, 115

stage at diagnosis, 81

trials of screening, 82

unresolved issues in screening for, 86

lung density, abnormal decrease in, 51

causes of segmental and lobar opacities, 47

opacities conforming to anatomic boundaries, 45, 46, CD-ROMFig.15, CD-ROMFig.16

opacities not conforming to anatomic boundaries, multiple nodular, 49, 49, CD-ROMFig.22, CD-ROMFig.23, CD-ROMFig.24, CD-ROMFig.25, CD-ROMFig.26

regional patchy multifocal and diffuse consolidations, 47, 48, 48, CD-ROMFig.17, CD-ROMFig.18

solitary nodular, 48, 49, CD-ROMFig.20

see also pulmonary hyperlucency

lung function, antibiotic use in COPD exacerbations and, 238

antibiotic use in cystic fibrosis and, 403, 406

corticosteroid use in farmer’s lung and, 517

early studies of inhaled corticosteroid use in COPD, 257

improvement in COPD patients on oral corticosteroids cf. placebo, 278

inhaled corticosteroids and baseline lung function, 260

intravenous aminophylline use in acute exacerbations of COPD, 236

tiotropium cf. placebo in COPD, 253–254

variation and asthma treatment, 139

lung function testing, 25–33

as a measure of hospitalization in asthmatics, 124

bronchiectasis and, 352

diagnostic properties of, 29

for hypersensitivity pneumonitis, 513

in asthmatics given omalizumab, 226

in cystic fibrosis, 367

literature searches for, 25

routine techniques, 25

use in diagnosis of dyspnoea, 18

use in preoperative risk assessment, 31

Lung Health III study, 260, 261

lung parenchyma, 45

lung resection, lung function testing before, 31

lung scintigraphy, in haemodynamically stable pulmonary embolism patients, 74

use in pulmonary embolism diagnosis, 69

lung transplantation, chronic rejection after early diagnosis of, 29

in bronchiectasis, 356

lung volume reduction surgery as a bridge to, 294

use in cryptogenic fibrosing alveolitis, 485

use in cystic fibrosis, 378

lung volume reduction surgery, adverse events, 292

air leaks after, 292

anaesthetic technique, 287

as a bridge to transplant, 294

beneficial effects, 289

comparative efficacy and cost, 294

comparison of techniques, 289

description of treatment, 287

effect on survival, 292

effects on dyspnoea, 289

effects on exercise capacity, 290

effects on FEV, 289

effects on lung volume, 290

effects on oxygenation requirement, 290

exclusion criteria for patients, 289

history of use, 285

in COPD, 285–295

inclusion criteria for patients, 288

long-term outcomes, 293

mechanisms by which it works in COPD, 286

mechanisms of benefit, 286

mortality after, 289

National Emphysema Treatment Trial (NETT), 285, 291
new techniques, 294
patient assessment algorithm, 288
postoperative management, 289
prediction of response, 292
preoperative assessment for, 287
RCT results, 290
summary for clinicians, 295
summary of treatment effects, 291
surgical technique, 287
use in obstructive diseases other than COPD, 294
lung volumes, as measure of hyerinflation, 30
effect of lung volume reduction surgery on, 290
measurements of, 25
reduction in COPD, 285–295
lungs,
appearance on X-ray, 45
bilateral lucent, 51, 51, CD-ROM Fig.27
consolidation of, 53, 54, 54
CT imaging of, 58, 58
differential diagnosis of, 53
CT imaging of, 58
ground-glass opacity in, 53
honeycombing on CT, 56
long-standing fibrosis in, 53
linear opacities on CT scan, 54
magnetic resonance imaging (MRI),
methylprednisolone, doses for acute exacerbations of COPD, 235
methylxanthines,
doses for acute exacerbations of COPD, 235
guidelines for use in acute exacerbations of COPD, 236
mortality,
after lung volume reduction surgery, 289
approach to in palliative care, 486
effect of lung volume reduction surgery for COPD on, 292
from community-acquired pneumonia, and pneumococcal vaccine, 316,
from influenza virus infection, 335
from community-acquired pneumonia, and pneumococcal vaccine, 316
from multiple sclerosis, influenza virus vaccination in, 338
from malignant pleural effusions, 527
in acute respiratory failure after non-invasive ventilation cf. usual medical care, 431
inhaled corticosteroid use in COPD and, 263
linked with salmeterol therapy, 144
MRI, see under magnetic resonance imaging
mucolytic agents,
in bronchiectasis, 354
in cystic fibrosis management, 369, 371
multidetector CT, see under computed tomography
multiple sclerosis, influenza virus vaccination in, 338
Mycobacterium avium-intracellulare, 510
Mycobacterium malmoense in bronchiectasis, 352
Mycobacterium abscessus in bronchiectasis, 352
Mycobacterium kansasii
Mounier–Kuhn syndrome, 350
MRD, see under Results in MRI
multiple睡意テスト, 449
use in asthmatics, 127, 128
use in cystic fibrosis management, 369, 371
use in bronchiectasis, 352
use in asthma after negative challenge, 15
mortality, after lung volume reduction surgery, 289
approach to in palliative care, 486
effect of lung volume reduction surgery for COPD on, 292
from community-acquired pneumonia, and pneumococcal vaccine, 316,
from influenza virus infection, 335
from community-acquired pneumonia, and pneumococcal vaccine, 316
from multiple sclerosis, influenza virus vaccination in, 338
from malignant pleural effusions, 527
in acute respiratory failure after non-invasive ventilation cf. usual medical care, 431
inhaled corticosteroid use in COPD and, 263
linked with salmeterol therapy, 144
prediction of from spirometry, 28
prediction of in community-acquired pneumonia, 310
screening for lung cancer and, 82
Mourad–Kuhn syndrome, 350
MRI, see under magnetic resonance imaging
mucolytic agents,
in bronchiectasis, 354
in cystic fibrosis management, 369, 371
multidetector CT, see under computed tomography
multiple sclerosis, influenza virus vaccination in, 338
Multiple Sleep Latency Test, 449, 451
Mycobacterium abscessus in bronchiectasis, 352
Mycobacterium avium-intracellulare, 510
in bronchiectasis, 352
in cystic fibrosis, 363, 366
Mycobacterium malmoense in bronchiectasis, 352
new techniques, 294
patient assessment algorithm, 288
postoperative management, 289
prediction of response, 292
preoperative assessment for, 287
RCT results, 290
summary for clinicians, 295
summary of treatment effects, 291
surgical technique, 287
use in obstructive diseases other than COPD, 294
lung volumes, as measure of hyerinflation, 30
effect of lung volume reduction surgery on, 290
measurements of, 25
reduction in COPD, 285–295
lungs,
appearance on X-ray, 45
bilateral lucent, 51, 51, CD-ROM Fig.27
consolidation of, 53, 54, 54
cystic airspaces in, 58
decreased attenuation on CT, 58
ground-glass opacity in, 53
honeycombing on CT, 56
linear opacities on CT scan, 54
magnetic resonance imaging (MRI),
methylprednisolone, doses for acute exacerbations of COPD, 235
methylxanthines,
doses for acute exacerbations of COPD, 235
guidelines for use in acute exacerbations of COPD, 236
mortality,
after lung volume reduction surgery, 289
approach to in palliative care, 486
effect of lung volume reduction surgery for COPD on, 292
from community-acquired pneumonia, and pneumococcal vaccine, 316,
from influenza virus infection, 335
from community-acquired pneumonia, and pneumococcal vaccine, 316
from multiple sclerosis, influenza virus vaccination in, 338
from malignant pleural effusions, 527
in acute respiratory failure after non-invasive ventilation cf. usual medical care, 431
inhaled corticosteroid use in COPD and, 263
linked with salmeterol therapy, 144
prediction of from spirometry, 28
prediction of in community-acquired pneumonia, 310
screening for lung cancer and, 82
Mourad–Kuhn syndrome, 350
MRI, see under magnetic resonance imaging
mucolytic agents,
in bronchiectasis, 354
in cystic fibrosis management, 369, 371
multidetector CT, see under computed tomography
multiple sclerosis, influenza virus vaccination in, 338
Multiple Sleep Latency Test, 449, 451
Mycobacterium abscessus in bronchiectasis, 352
Mycobacterium avium-intracellulare, 510
in bronchiectasis, 352
in cystic fibrosis, 363, 366
Mycobacterium malmoense in bronchiectasis, 352
new techniques, 294
patient assessment algorithm, 288
postoperative management, 289
prediction of response, 292
preoperative assessment for, 287
RCT results, 290
summary for clinicians, 295
summary of treatment effects, 291
surgical technique, 287
use in obstructive diseases other than COPD, 294
lung volumes, as measure of hyerinflation, 30
effect of lung volume reduction surgery on, 290
measurements of, 25
reduction in COPD, 285–295
lungs,
appearance on X-ray, 45
bilateral lucent, 51, 51, CD-ROM Fig.27
consolidation of, 53, 54, 54
cystic airspaces in, 58
decreased attenuation on CT, 58, CD-ROM Fig.43, CD-ROM Fig.44
ground-glass opacity in, 53, 53
honeycombing on CT, 56, CD-ROM Fig.37
linear opacities on CT scan, 54, 55
nodular opacities on CT, 56, 57, 57, CD-ROM Fig.38, CD-ROM Fig.40
perfusion scans of, 69
peribronchovascular thickening on CT, 54, 55
septal lines on CT, 55, 55, CD-ROM Fig.35
subpleural thickening on CT, CD-ROM Fig.37
lymphoma, diagnosis from pleural effusion, 526
macrolides,
cf. β-lactams in COPD, 392
cf. quinolones in COPD, 392, 395, 396
cf. tetracyclines in COPD, 392
in bronchiectasis, 399
use in acute exacerbations of COPD, 392
use in cystic fibrosis, 376, 406, 406, 407, 408
magnesium, oral supplements and asthma, 197
magnesium sulphate, intravenous, use of and hospitalization of acute asthmatics, 127, 128
magnetic resonance imaging (MRI),
development for use in pulmonary embolism diagnosis, 72, 73
use in search for residual DVT, 71
Maintenance of Wakefulness Test, 451
mandibular advancement splints,
cf. other treatments, 457
use in OSAHS, 456
mastectomy, abnormal decrease in density of chest wall on X-ray after, 39
Mayo Lung Project, 82, 83
mediastinum,
causes of mass, 45
changes in configuration or line of, 44, 45
changes in density, 44
CT imaging of, 43
diffuse widening of, 44
patterns on CT, 46
posterior mass, CD-ROM Fig.13
shift of, 43
causes of, 44
signs of pathology, 43
widening of, 43, 44, CD-ROM Fig.9, CD-ROM Fig.10, CD-ROM Fig.11
Medical Outcomes Survey, short-form, 451
medication, delivery route and adherence, 98
MEDLINE, description, 7
mefloquine use in OSAHS, 458
melagatran, 543
mesothelioma, diagnosis from pleural effusion, 526
Index

ouabain use in cystic fibrosis, 368
outcome,
adherence to medication use in asthmatics and, 99
role in clinical questions, 6
over-the-counter cough medicines,
cf. β-agonists and placebo, 306
RCT on, 305
use in bronchitis, 304
oxygen,
dangers of smoking whilst using, 465, 466
long-term therapy, use in cystic fibrosis, 378
supplemental doses for acute exacerbations of COPD, 235
supplementation during exercise training, 423
oxygen saturation, as a measure for hospitalization in asthmatics, 124
oxygen therapy,
air travel and use of, 470
cost-effectiveness, 466
dangers of smoking whilst using, 465, 466
for hypoxaemia in cystic fibrosis, 484
in COPD and assisted ventilation, 467, 468
nocturnal, 465
see also long-term oxygen therapy
use in cystic fibrosis exacerbations, 381
vs. no oxygen therapy, 465
oxygenation, effect of lung volume reduction surgery on, 290
oxyphenbutazone use in sarcoidosis, 503, 504
oxytetracycline in bronchiectasis, 399
Paced Auditory Serial Addition Task, 452
palliative care, in cryptogenic fibrosing alveolitis, 486
pancreatic function tests in cystic fibrosis management, 367
parapneumonic effusion, 529
classification, 529
recommendations for management, 532
treatment, 530
decortication, 532
intrapleural fibrinolytics, 530
observation, 530
thoracoscopy with lysis of adhesions, 531
tube thoracostomy, 530
patient education, see under education
PE, see under pulmonary embolism
peak expiratory flow (PEF),
chronic cough and, 13
improvement on inhaled corticosteroids, 150
measures in acute dyspnoea, 20
morning vs. evening values and asthma treatment, 139
preoperative risk assessment and, 31
ROC curves for dyspnoea, 19
use in diagnosis of dyspnoea, 18
peak expiratory flow rate (PEFR),
as a measure of hospitalization in asthmatics, 124
effect of breathing exercises on in asthma, 200, 202
peak flow meter, assessment of use by asthmatics, 96
PEF, see under peak expiratory flow
penicillamine use in cystic fibrogenic fibrosing alveolitis, 480, 482
penicillins,
cf. cephalosporins in COPD, 392
in bronchiectasis, 399
use with azlocillin in cystic fibrosis, 402
pentasaccharide, use of synthetic in treatment of PE, 543
pentoxifylline use in sarcoidosis, 502, 503
perennial allergic rhinitis, 15
pertussis, bronchiectasis after, 349
pharmacotherapy, effectiveness in smoking cessation interventions, 119
phenprocoumon, use in PE, 544–546
phosphodiesterase inhibitors,
use in arterial pulmonary hypertension, 567
use in cryptogenic fibrosing alveolitis, 485
use in sarcoidosis, 502, 503
physostigmine use in OSAHS, 458
PICO methodology, 7
pigeon-breeder’s disease, 510
high-resolution CT of, 512
specific antibodies in, 514
PIOPED study, 69
pirfenidone, use in cryptogenic fibrosing alveolitis, 482, 483
PISA-PED study, 69
PLCO Trial, 83
pleura,
abnormal decrease in density, 40, 41
abnormal increase in density, 40, 41, CD-ROM Fig. 4
opioidities of, 40
pleural disease, 521–532
pleural effusion, 40, CD-ROM Fig. 4
diagnosis of malignant, 526
diagnosis of pleural tuberculosis, 525
diagnosis of undiagnosed,
by bronchoscopy, 527
by CT scan, 527
by thoracoscopy, 527
by thoracotomy, 527
diagnostic tests of pleural fluid, 524
management of,
malignant, 527
indwelling catheters, 528
pleurodesis, 528
post coronary artery bypass surgery, 529
tuberculous, 529
separation of transudates from exudates, 524
with hilar enlargement, 41
with large cardiac silhouette, 41
pleural malignant mesothelioma, appearance on X-ray and CT, 41
pleurodesis,
agents used for, 528
use in malignant pleural effusions, 528
use in primary pneumothorax, 522
pneumococcal vaccine,
administration to people at risk of community-acquired pneumonia, 314
Cochrane systematic review of use, 315, 316, 317
Pneumocystis carinii, acute respiratory failure in HIV-positive patients and, 434
pneumonia,
acute, appearance on X-ray, 46, CD-ROM Fig. 15
acute interstitial, 478
acute respiratory failure in, 433
as a complication of influenza virus infection, 335
community-acquired,
as a cause of acute respiratory failure, 429
parapneumonic effusions in, 529
community-acquired, 309–318
bacterial causes of, 309
Cochrane systematic reviews of pneumococcal vaccine use for, 315, 316, 317
CURB severity score, 310
definition of, 309
diagnostic evaluation, 310
guidelines for diagnosis and management, 309
management and risk stratification, 310
prediction of mortality in, 310
risk stratification, 310
summary for clinicians, 318
treatment of,
antibiotic therapy, 311
causative agent and choice of, 311
in community settings, 312
in hospital setting, 313
risk stratification and, 310, 311, 312
vaccination against, 314
desquamative interstitial, 478
idiopathic interstitial, 477
non-specific interstitial, 477
usual interstitial, 477
pneumonitis, hypersensitivity, 509–518
pneumothorax,
appearance on X-ray, 41
atypical signs, 41, 42
primary,
diagnosis, 521
treatment, 522
aspiration, 522
observation, 522
thoracoscop, 522
thoracotomy, 523
tube thoracostomy, 522
tube thoracostomy with chemical pleurodesis, 522
risk in cystic fibrosis, 363
secondary,
diagnosis, 523
prevention of recurrence, 524
treatment, aspiration, 523
observation, 523
tube thoracostomy, 523
typical signs of, 40
population, role in clinical questions, 6
portopulmonary hypertension, 562
positive expiratory pressure in bronchiectasis, 354
postnasal drip syndrome,
as cause of chronic cough, 13
therapies for, 14
postural drainage and chest percussion/vibration,
in bronchiectasis, 353
in cystic fibrosis, 368, 369
predictors,
for success of non-invasive ventilation in acute respiratory failure, 436
of hypersensitivity pneumonitis, 511
of response to lung volume reduction surgery in COPD, 292
parapneumonic effusions in community-acquired pneumonia, 529
prediction of response to oral corticosteroids in COPD, 282
prednisolone,
cf. beclomethasone in COPD, 258
use in active hypersensitivity pneumonitis, 516
prednisone cf. placebo, after acute exacerbations of COPD, 240
pregnancy, management of PE in, 552
preoperative risk assessment, 31
presenting symptoms, 13–22
primary pneumothorax, 521–523
Profile of Mood States, 452
prognosis,
in interstitial lung disease, 30
role of spirometry in, 28
proton pump inhibitors, use in gastro–oesophageal reflux disease, 14
protrypitline use in OSAHS, 458
Pseudomonas aeruginosa,
in bronchiectasis, 352, 398
in cystic fibrosis, 362, 366, 400
acquisition of, 364
chronic infection, 363
chronic infection in exacerbations, 379
intravenous antipseudomonal antibiotics in, 373
nebulized antipseudomonal antibiotics, 372–373
oral antibiotics, 374
specific antipseudomonal antibiotics in, 403
Pseudomonas sp., risk factors for infection in community-acquired pneumonia patients, 314
psychogenic cough, see under cough
psychological support for respiratory rehabilitation, 417
pulmonary angiography,
as gold standard for pulmonary embolism diagnosis, 66
CTPA, use in pulmonary embolism diagnosis, 70
in haemodynamically stable pulmonary embolism patients, 75
use in pulmonary embolism diagnosis, 65
pulmonary embolectomy, 550
pulmonary embolism (PE), 537–553
acute,
bolus thrombolysis in, 549
RCT of thrombolytic agent use in, 548
acute massive, support measures in, 552
basic tests for, 73
catheter transvenous embolectomy for, 551
clinical appearance, 63
complications of thrombolytic therapy in, 549
diagnostic strategies, 63–75
ECG tests for, 65
estimation of pretest clinical likelihood, 67
frequency of clinical signs, 64
frequency of symptoms, 64
haemodynamic consequences of, 65
haemodynamic instability in acute massive, 73
haemodynamically stable patients, 74
integrated diagnostic approach, 73
lack of guidelines for diagnosis, 64
lung scintigraphy as test for, 69
management in pregnancy, 552
non-diagnostic tests in, 71
prediction rules for, 68
presence of leg DVT in, 65
probability of,
from PIOPED study, 69
from PISA-PED study, 69
processes leading to, 537
pulmonary embolectomy, 550
risk factors for, 67
scheme for treatment of, 538
search for residual DVT and diagnosis, 71
sensitivity and specificity of tests, 65
specific problems in diagnosis, 64
thrombolytic agent use in, 546
treatment with low-molecular-weight heparin, 541–543
treatment with oral anticoagulants, 544–546
treatment with synthetic pentasaccharide, 543
treatment with direct thrombin inhibitors, 543
treatment with unfractionated heparin, 538–541
useless tests for, 72
venous interruption for, 551
weight-based heparin dosing nomogram, 540
pulmonary endarterectomy, use in pulmonary hypertension, 563
pulmonary fibrosis, flow–volume loop for, 26
pulmonary function testing, see under lung function testing, 25
pulmonary hyperlucency,
causes of, 51
solitary or multiple defects, 51
unilateral or bilateral, 51
pulmonary hypertension, 559–568
arterial,
beraprost for, 565
Bosentan for, 563
calcium channel blockers for, 567
cf. venous, 562
epoprostenol for, 564
iloprost for, 566
phosphodiesterase inhibitors for, 567
therapy decisions, 567
treprostinil for, 565
treatment with bosentan, 563
treatment with endogenous nitric oxide, 563
treatment with prostacyclins, 563
unilateral or bilateral, 51
vascular, 559–568
beraprost for, 565
Bosentan for, 563
calcium channel blockers for, 567
cf. venous, 562
epoprostenol for, 564
iloprost for, 566
phosphodiesterase inhibitors for, 567
therapy decisions, 567
treatment with bosentan, 563
treatment with endogenous nitric oxide, 563
treatment with prostacyclins, 563
unilateral or bilateral, 51
vascular, 559–568
beraprost for, 565
Bosentan for, 563
calcium channel blockers for, 567
characteristics, 563
cf. venous, 562
epoprostenol for, 564
iloprost for, 566
phosphodiesterase inhibitors for, 567
therapy decisions, 567
unilateral or bilateral, 51
vascular, 559–568
beraprost for, 565
Bosentan for, 563
calcium channel blockers for, 567
cf. venous, 562
epoprostenol for, 564
iloprost for, 566
phosphodiesterase inhibitors for, 567
therapy decisions, 567
unilateral or bilateral, 51
physical examination, 559
pivotal trials in, 564
severity assessment, 561
summary for clinicians, 567, 568
symptoms, 559
therapy,
medications with no use in, 563
supportive and anticoagulant, 562
venous, therapy of, 563
WHO classification, 560
WHO functional assessment classification, 561
WHO nomenclature, 560
with COPD, 563
pulmonary nodules,
appearance of and diagnosis, 57
appearance on CT, 56, CD-ROM Fig. 38, CD-ROM Fig. 40
causes of, 57
coarse, 49
fine, 50
linear, 50
solitary, 48
pulmonary sarcoidosis, 491–497
pulse oximetry, as a measure of hospitalization in asthmatics, 124
qualitative systematic review, description, 4
quality of life,
anti-immunoglobulin E treatment of asthma and, 226
assessment in bronchiectasis, 353
dyspnoea and, 419
effect of CPAP on in OSAHS patients, 455
effect of oxygen therapy on in COPD, 466, 469
measures of in OSAHS, 451
response to inhaled corticosteroids in COPD, 262
questions,
arising from cough cases, 15
components of, 6
considerations when posing, 7
development of, 6
quinolones,
cf. β-lactams, in COPD, 392, 394, 395
cf. macrolides, in COPD, 392, 395, 396
use in acute exacerbations of COPD, 392
use in cystic fibrosis exacerbations, 379
radiation therapy, use in sarcoidosis, 503, 504
randomized controlled trials (RCT),
for antibiotic use in acute exacerbations of bronchiectasis, 398
level of evidence from, 4
of ipratropium bromide use in COPD, 247, 248
of long-term nocturnal non-invasive ventilation, 444
of long-term non-invasive ventilation in COPD, 441
of long-term oxygen therapy in stable COPD, 464
of lung cancer screening, 84
of lung volume reduction surgery in COPD, 290
of short-term non-invasive ventilation in COPD, 440, 441
of thrombolytic agent use in acute PE, 548
of tiotropium in stable COPD, 252
on bronchitis and sinusitis, 304
on respiratory rehabilitation, 419
on use of nebulized antibiotics in cystic fibrosis, 403, 406
use of antibiotics in acute exacerbations of COPD, 390, 391
RCT, see under randomized controlled trials
recombinant human deoxyribonuclease, see under DNase
reflux oesophagitis in cryptogenic fibrosing alveolitis, 484
rehabilitation, see under respiratory rehabilitation
relaxation use in asthma, 199, 201
resectional surgery in bronchiectasis, 356
respiratory bronchiolitis-associated interstitial lung disease, 478
respiratory disturbance index, 448
respiratory effort-related arousal event, 448
respiratory muscle strength, measurement of, 25
respiratory rehabilitation,
anabolic hormone supplements and, 423
cf. control results, 420, 421
definition, 417
description of treatment, 417
dyspnoea after, 422
enhanced follow-up, 425
exercise maintenance, 425
exercise training for, 417
functional exercise capacity, 419
in COPD, 417–426
inspiratory muscle training, 419
literature search on, 418
maintenance programmes, 424
maximal exercise capacity, 419
non-physiological rationale for, 418
nutritional supplementation and, 423
oxygen therapy and assisted ventilation in COPD and, 467, 468
patient factors in, 424
physiological rationale for, 418
programme duration, 424
programme location, 424
programme repeats, 425
RCT findings, 419
summary for clinicians, 426
supplemental oxygen during exercise training, 423
use of oxygen therapy in COPD and, 466
ventilatory support during exercise training, 424
restrictive lung disease, flow-volume loop for, 26
reteplase, 546
rheumatoid arthritis, interstitial lung disease in, 479
rhinosinusitis, bronchiectasis and, 352
rib, abnormal increase in density on CT indicating rib metastasis, 39, CD-ROM Fig. 1
rimantadine, 340
cf. amantadine, 343
sabeluzole use in OSAHS, 458
Saccharopolyspora rectivirgula, 510
specific antibodies for in hypersensitivity pneumonitis, 513
salbutamol doses for acute exacerbations of COPD, 235
salmeterol,
cf. fluticasone, 144
cf. ipratropium bromide in COPD, 250
definition and use, 136
mortality and without inhaled corticosteroids, 144
safety and efficacy, 144
salt reduction and asthma, 197
sarcoidosis, 491–505
chronic disease treated with systemic corticosteroids, 497
inhaled corticosteroids for, 492, 495, 496
oral corticosteroids for, 491, 493, 494
pulmonary nodules on CT, CD-ROM Fig. 38
recommendations for management, 504
treatments for, 492
adalimumab, 500, 502
alternatives to corticosteroids, 497
chronic disease treated with systemic corticosteroids, 497
inhaled corticosteroids for, 492, 495, 496
oral corticosteroids for, 491, 493, 494
pulmonary nodules on CT, CD-ROM Fig. 38
recommendations for management, 504
treatments for, 492
azathioprine, 499, 501
chlorambucil, 499, 501
corticosteroids, 491–497
cyclophosphamide, 499, 501
cyclosporin, 502, 503
etanercept, 300, 502
fumaric acid esters, 503, 504

590
Index

591
steam inhalation for bronchitis and sinusitis, 305
SteerClear, 452
Stenotrophomonas maltophilia, 363
in cystic fibrosis, 366, 400
Streptococcus pneumoniae,
   antibiotic resistance in, 309
   community-acquired pneumonia and, 309
   in bronchiectasis, 352
   in bronchitis, 301
   in community-acquired pneumonia, 311
   in COPD flare-ups, 238
   in sinusitis, 301
strepodornase, use in parapneumonic effusion therapy, 530, 531
streptokinase,
   use in parapneumonic effusion therapy, 530, 531
   use in PE, 546
summer-type hypersensitivity pneumonitis, 510
surgery,
   lung volume reduction in COPD, 285–295
   resectional surgery in bronchiectasis, 356
   use in OSAHS, 459
sweat electrolyte analysis,
   bronchiectasis and, 351
   use in diagnosis of cystic fibrosis, 364
Symbicort®,
   adjustable dosing, 222
   comparison with inhaled corticosteroids alone, 219
   strategies for use, 221
synthetic pentasaccharide use in PE, 543
systematic reviews,
   from Cochrane collaboration, 4, 5
   levels of evidence from, 4
   on CPAP in OSAHS, 453
   qualitative, 4
   terminology used in, 5
talc,
   administration in malignant pleural effusion, 528
   use in primary pneumothorax for pleurodesis, 522
telithromycin cf. amoxicillin/clavulanic acid, in COPD, 395
temperature-controlled radiofrequency tissue ablation,
   adverse effects after, 459
   cf. CPAP, 459
   efficacy in OSAHS, 459
tencetplase, 546
tension pneumothorax, description, 42
terminology,
   use in OSAHS, 448, 449
   used in systematic reviews, 5
tetracyclines,
   cf. macrolides, in COPD, 392
   use in acute exacerbations of COPD, 392
   use in primary pneumothorax for pleurodesis, 522
   use in sarcoidosis, 503, 504
thalidomide use in sarcoidosis, 502, 503
theophylline,
   long-acting β-2 agonists vs. in stable asthma, 143
   safety and efficacy cf. β-2 agonists, 144
   use in cystic fibrosis, 377
   use in OSAHS, 458
   vs. β-2 agonists, 138
Thermoactinomyces vulgaris, specific antibodies for in hypersensitivity
   pneumonitis, 513
thoracentesis use in pleural effusion diagnosis, 525
thoracoscopy,
   use in parapneumonic effusion therapy, 531
   use in primary pneumothorax, 522
   use in undiagnosed pleural effusion, 527
thoracotomy,
   use in primary pneumothorax, 523
   use in undiagnosed pleural effusion, 527
thrombin inhibitors, use of direct in treatment of PE, 543
thrombocytopenia heparin-induced, 541
thrombolytic agents,
   bolus thrombolysis, 549
   cf. heparin, 546, 547
   comparison of agents, 548
   complications of therapy in PE, 549
   examples of, 546
   use in acute PE, 548
   use in PE, 546
thymosarcoma, mediastinal widening and, 44, CD-ROMFig.11
thyroid tumour, metastatic, CD-ROMFig.23
ticarcillin use with tobramycin in cystic fibrosis, 402
time tension index, 440
tiotropium,
   cf. placebo in COPD, 253–254
   effect on symptoms and health status in COPD, 254
   pharmacological properties of, 245, 246
   prevention of COPD exacerbations by, 254
   RCT of use in stable COPD, 252
   see also anticholinergic agents
tissue plasminogen activator use in parapneumonic effusion therapy, 531
tobramycin,
   nebulized, in bronchiectasis, 399
   nebulized vs. nebulized colistin, 405
   nebulized vs. placebo, 405
   use with azlocillin in cystic fibrosis, 402
   use with ticarcillin in cystic fibrosis, 402
tracheobronchomegaly, 350
tracheomalacia, flow–volume loop for, 26
Trailmaking B tests, 452
transforming growth factor-β use in pleurodesis, 529
Transition Dyspnoea Index, 273
trauma, acute respiratory failure and chest trauma, 434
treprostinil, use in arterial pulmonary hypertension, 565
triage, by clinical likelihood of VTE in pulmonary embolism diagnosis, 65
triamcinolone, effect on lung function in COPD, 260
Trichosporon cutaneum, 510
troleandomycin use in treatment-resistant asthma, 209
tube thoracostomy,
   use in parapneumonic effusion therapy, 530
   use in primary pneumothorax, 522
   use in secondary pneumothorax, 523
tuberculosis, 321–332
   adherence to treatment, 325
   strategies to promote, 329, 330, 331
   adjunctive treatment,
      corticosteroids, 324
      laser therapy, 325
      Mycobacterium vaccae, 324
   case definition, 323
   chemotherapy,
      intermittent short-course, 324
      regimens less than 6 months’ duration, 324
      second-line antituberculosis drugs, 324
   standardized short-course, 323
   chemotherapy for, 323
   standardized short-course form, 323
   clinical features, 322
   clinical presentation, 321
   post-primary disease, 322
   primary disease, 322
diagnosis,
   culture, 322
   microscopy, 322
   radiography, 322
tuberculin skin test, 322
diagnosis of pleural, 525
epidemiology, 321
incidence, 321
mode of spread, 321
natural history of disease, 321
pleural effusions with, management of, 329
prevention,
 bacillus Calmette–Guérin, 325
directly observed therapy, 328
in HIV-infected and non-infected persons, 326
isoniazid in at-risk groups, 326
other interventions used, 327, 328
treatment of latent disease, 325, 327
summary for clinicians, 332
WHO definitions, 323
tumour markers, 526
tumour necrosis factor inhibitors,
toxicity of, 502
use in sarcoidosis, 500, 502
UK, lung cancer screening trials in, 85
ultrasound,
diaphragm imaging by, 43
use in chest wall examination, 39
unfractionated heparin, 538–541
University of Wales Institute of Science and Technology Mood Adaptive Checklist, 452
upper airway resistance syndrome, definition, 449
upper respiratory tract infections as cause of acute cough, 13
uridine triphosphate use in cystic fibrosis, 368
urokinase use in PE, 546
USA, lung cancer screening trials in, 85
usual interstitial pneumonia, 477
uric acid,
urate oxidase, 373
uranium hexafluoride, 542
uranium nitrate, 542
uranium, 542
uranium oxide, 542
uranium polycarbide, 542
urine,
uric acid, 373
urine markers, 526
urokinase, 546
va, see under alveolar volume
vaccination,
 against influenza virus, 335–344
cost-effectiveness, 338
inactivated vaccines, 336
live attenuated vaccines, 338
policies for and implementation of, 339
target groups, 339
use in cystic fibrosis, 377
bacillus Calmette–Guérin, 325
cost-effectiveness, 343
for prevention of community-acquired pneumonia, 314
use in cystic fibrosis for infection control, 374
Varidase use in parapneumonic effusion therapy, 531
venous interruption, 551
venous thromboembolism (VTE), 537–553
D-dimer tests for, 70
description, 537
direct thrombin inhibitors in, 543
optimal duration of vitamin K antagonist treatment, 544
outcome cf. PE, 538
pentasaccharide treatment and risk of, 543
risk factors for, 67
triage by clinical likelihood of, 65
ventilation,
non-invasive,
avoidance of intubation by use in COPD, 238
use in acute exacerbations of COPD and complications, 237
use in acute exacerbations of COPD cf. standard care alone, 238
ventilatory defects,
classification of, 26, 27
mixed, 26
obstructive, 26
restrictive, 26
vertebral fracture risk and corticosteroid dose, 108
vitamin C, supplementation and asthma, 197
vitamin D, use in osteoporosis with calcium, 112
vitamin K antagonists,
intensity of treatment, 544
optimal duration of treatment, 544
use in PE, 544–546
vitamins, fat-soluble, measures of in cystic fibrosis management, 367
volume assist-control ventilators, description, 429
VTE, see under venous thromboembolism
warfarin use in PE, 544–546
websites, examples for evidence-based medicine, 9
Wegener’s granulomatosis, CD-ROM Fig.28
weight loss, effect on OSAHS, 458
wheeze,
as predictor of COPD, 22
bronchial hyper-reactivity and, 21
diagnostic strategies for, 21
dyspnoea and, 21
predictive value of, 21
Wisconsin Sleep Cohort Study, 449
written action plans, for asthma, 187
x-rays, 37–59
abnormal decrease in density, 40
chest wall, 39, 40, CD-ROM Fig.2
pleura, 40, 41
abnormal high position of diaphragm, CD-ROM Fig.6
abnormal increase in density, 40
pleura, 40, 41, CD-ROM Fig.4
appearance of lung on, 45
in bronchiectasis, 351
as a test for hypersensitivity pneumonitis, 511
cf. low-dose spiral CT for lung cancer screening, 83
chest wall,
abnormal decrease in density, 39
following mastectomy, 39, CD-ROM Fig.2
abnormal increase in density, 39, 40
chest wall opacities on, 39
diagnosis from, 37
hilar mass or enlargement on, 52, CD-ROM Fig.29
hilar shadows on, 52, CD-ROM Fig.30
regional patchy multifocal and diffuse consolidations, 47, 48, 48,
CD-ROM Fig.22, CD-ROM Fig.23, CD-ROM Fig.24, CD-ROM Fig.25, CD-ROM Fig.26
recognition of abnormalities on, 38
recognition of patterns on, 38
use in diagnosis of haemoptysis, 17
use in diagnosis of sinusitis, 302
use in pulmonary embolism, 71
use in tuberculosis diagnosis, 322
Ximelagatran, 543
yellow nail syndrome, 350
yoga use in asthma, 199, 202
zaflurukast,
cf. placebo as add-on therapy, 173
risk of asthma exacerbation whilst on, 171
zanamivir, 341
cf. placebo, 343